Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers

J Biomed Sci. 2021 Apr 8;28(1):24. doi: 10.1186/s12929-021-00719-5.

Abstract

Thyroid hormone analogues-particularly, L-thyroxine (T4) has been shown to be relevant to the functions of a variety of cancers. Integrin αvβ3 is a plasma membrane structural protein linked to signal transduction pathways that are critical to cancer cell proliferation and metastasis. Thyroid hormones, T4 and to a less extend T3 bind cell surface integrin αvβ3, to stimulate the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway to stimulate cancer cell growth. Thyroid hormone analogues also engage in crosstalk with the epidermal growth factor receptor (EGFR)-Ras pathway. EGFR signal generation and, downstream, transduction of Ras/Raf pathway signals contribute importantly to tumor cell progression. Mutated Ras oncogenes contribute to chemoresistance in colorectal carcinoma (CRC); chemoresistance may depend in part on the activity of ERK1/2 pathway. In this review, we evaluate the contribution of thyroxine interacting with integrin αvβ3 and crosstalking with EGFR/Ras signaling pathway non-genomically in CRC proliferation. Tetraiodothyroacetic acid (tetrac), the deaminated analogue of T4, and its nano-derivative, NDAT, have anticancer functions, with effectiveness against CRC and other tumors. In Ras-mutant CRC cells, tetrac derivatives may overcome chemoresistance to other drugs via actions initiated at integrin αvβ3 and involving, downstream, the EGFR-Ras signaling pathways.

Keywords: Colorectal Cancer; Epidermal growth factor receptor; Integrin αvβ3; NDAT; Ras mutation.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Colorectal Neoplasms / prevention & control*
  • Genes, erbB-1
  • Genes, ras
  • Humans
  • Integrin alphaVbeta3 / therapeutic use*
  • Signal Transduction*
  • Thyroxine / therapeutic use*

Substances

  • Antineoplastic Agents
  • Integrin alphaVbeta3
  • Thyroxine